Verana Health and Guardant Health announced a partnership to provide biopharma researchers with combined precision medicine data access using Verana’s regulatory-grade therapeutic-specific electronic health record datasets and Guardant’s clinicogenomic testing results. The companies said the joint data environment supports correlations between biomarkers, treatment decisions, and longitudinal clinical outcomes. The collaboration expands Verana’s breadth into solid tumors—specifically lung, breast, and colorectal cancers—while Guardant’s datasets cover tumor profiling through recurrence and therapy response monitoring. Both companies framed the integration as accelerating biomarker validation and supporting more economical drug development. For sponsors, the immediate value proposition is improved hypothesis testing using real-world oncology care pathways paired with standardized molecular testing and deeper longitudinal records.